StockNews.com cut shares of Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) from a hold rating to a sell rating in a report released on Thursday morning. A number of other research analysts have also issued reports on IOVA. Wells Fargo & Company upgraded Iovance Biotherapeutics from an equal weight rating to an overweight rating and increased […]
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) has earned an average rating of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokers […]
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Rating) has received an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. […]
683 Capital Management LLC lessened its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) by 41.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,000,000 shares of the biotechnology company’s stock after selling 705,000 shares during the period. 683 Capital Management LLC […]